Conference Description:

With the US in the midst of an opioid crisis, it has never been more critical for the pharmaceutical, biotechnology and academic fields to unite in a common goal to innovate and accelerate the discovery and development of novel non-opioid therapies to treat pain.

This summit and its expert speaker faculty will update you on the latest and novel RandD efforts currently ongoing in discovery and optimization of non-opioid analgesic targets and their mechanism of action. In addition, the inaugural Non-Opioid Pain Drug Development Summit will be your dedicated platform to overcome translational challenges such as animal model predictive value, biomarker identification, and proving efficacy against placebo effect.

http://www.non-opioiddrugdevelopment.c om/

September 27-28, 2018

Contact:
[email protected]
+ 1 617 455 4188

URLs:
Brochure: https://go.evvnt.com/234426-0?pid=154
Tickets: https://go.evvnt.com/234426-1?pid=154

Prices:
Conference + 1 Workshop Earlybird (Book by 15/06/18): USD 1798.0
Conference + 1 Workshop (standard rate): USD 2498.0
Conference Earlybird (Book by 15/06/18): USD 1299.0
Conference (Standard rate): USD 1999.0
Workshop: USD 499.0

Speakers: Mary Ann Pellymounter (NIH/NINDS/Division of Translational Research), Daniel Klamer (Anavex Life Sciences Corp.), Kerrie Brady (Centrexion Corp), Crist Frangaki (Achelios Therapeutics), Lucio Rovati (Rottapharm Biotech), Silviu Itescu (Mesoblast Ltd.)

Time: 8:00 am - 4:00 pm